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Background: A little is known about pharmacotherapy for critical limb ischemia (CLI). We sought to evaluate the influence of cilostazol on clinical 
outcomes after endovascular therapy (EVT) in patients with CLI.
Methods: This study was a retrospective multicenter clinical study. Total 134 patients (167 critical limbs) successfully undergoing EVT for 
femoropopliteal disease were enrolled and divided into two groups: patients receiving cilostazol (n=109) in addition to standard therapy or not 
(n=58). Restenosis was evaluated >2.4 of peak systolic velocity ratio by duplex ultrasound or > 50% stenosis by angiography. Primary patency was 
defined as treated vessel without restenosis and repeat revascularization.
Results: Mean follow-up period was 502 +/- 346 days. Primary patency rate was significantly higher in the cilostazol group compared to the 
control group (39% vs. 17%, p=0.009). Multivariate Cox regression analysis indicated that cilostazol administration, and TASCII class C/D were 
predictors of primary patency after EVT. All-death, Limb salvage rate and surgical revascularization were not statistically significant in both groups.
Conclusions: Cilostazol administration may lead to improved primary patency in patients with CLI due to femoropopliteal artery disease.
